Akebia Therapeutics Inc (NASDAQ: AKBA) is 0.53% higher on its value in year-to-date trading and has touched a low of $0.80 and a high of $2.48 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The AKBA stock was last observed hovering at around $1.98 in the last trading session, with the day’s loss setting it -0.07%.
Currently trading at $1.91, the stock is -12.12% and -5.55% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.54 million and changing -3.54% at the moment leaves the stock 23.50% off its SMA200. AKBA registered 31.72% gain for a year compared to 6-month gain of 28.19%.
The stock witnessed a -19.41% loss in the last 1 month and extending the period to 3 months gives it a 6.70%, and is -9.48% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.16% over the week and 3.81% over the month.
Akebia Therapeutics Inc (AKBA) has around 167 employees, a market worth around $416.73M and $169.88M in sales. Profit margin for the company is -27.07%. Distance from 52-week low is 138.75% and -22.98% from its 52-week high. The company has generated returns on investments over the last 12 months (-34.53%).
with sales reaching $37.36M over the same period.The EPS is expected to shrink by -9.12% this year, but quarterly earnings will post -22.39% year-over-year. Quarterly sales are estimated to shrink -33.52% in year-over-year returns.
The shares outstanding are 211.54M, and float is at 209.46M with Short Float at 6.90%.
The top institutional shareholder in the company is BLACKROCK INC. with over 11.64 million shares valued at $11.87 million. The investor’s holdings represent 5.6786 of the AKBA Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 9.28 million shares valued at $9.46 million to account for 4.526 of the shares outstanding. The other top investors are ALERCE INVESTMENT MANAGEMENT, L.P. which holds 5.75 million shares representing 2.7409 and valued at over $5.86 million, while GEODE CAPITAL MANAGEMENT, LLC holds 2.1632 of the shares totaling 4.54 million with a market value of $4.63 million.
Akebia Therapeutics Inc (AKBA) Insider Activity
The most recent transaction is an insider sale by Butler John P., the company’s CEO and President. SEC filings show that Butler John P. sold 144,250 shares of the company’s common stock on Feb 03 ’25 at a price of $2.10 per share for a total of $0.3 million. Following the sale, the insider now owns 2.6 million shares.
Akebia Therapeutics Inc disclosed in a document filed with the SEC on Feb 03 ’25 that Burke Steven Keith (SVP, Chief Medical Officer) sold a total of 50,506 shares of the company’s common stock. The trade occurred on Feb 03 ’25 and was made at $2.10 per share for $0.11 million. Following the transaction, the insider now directly holds 0.82 million shares of the AKBA stock.
Still, SEC filings show that on Feb 03 ’25, Malabre Richard C (SVP, Chief Accounting Officer) disposed off 30,202 shares at an average price of $2.10 for $63424.0. The insider now directly holds 280,248 shares of Akebia Therapeutics Inc (AKBA).
